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ABSTRACT
VINYL CHLORIDE-DIET INTERACTIONS IN LIVER DISEASE:
POTENTIAL ROLES OF AUTOPHAGY AND ENERGY MANAGEMENT
Anna L. Lang
May 12, 2016
Vinyl chloride (VC) is a prevalent environmental toxicant that has been
shown to cause liver injury at high, occupational exposures. However, most studies
have not addressed interactions of low doses with risk-modifying factors. This
study aims to explore low-level VC metabolite exposure interactions with other
potential risk-modifying factors and their effect on underlying liver disease. We
examined sub-hepatotoxic effects of a VC metabolite (chloroethanol, CE) in two
murine models of liver injury using ethanol and lipopolysaccharide (LPS). In both,
CE significantly enhanced liver injury when compared to either ethanol or LPS
alone. Previous studies have shown an increase in mTOR activity with CE alone.
Here, we used a pharmacologic inhibitor of mTOR, rapamycin, to study its effect
on injury progression. Indeed, the addition of rapamycin significantly attenuated
liver injury, hepatic steatosis, and inflammatory markers in the CE + LPS model.
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INTRODUCTION
I.

Vinyl Chloride

Vinyl chloride monomer (VC) is a pervasive environmental organochlorine
toxicant. It is ranked #4 on the CDC’s Agency for Toxic Substances and Disease
Registry (ATSDR) Substance Priority List;(1) with an annual production recently
estimated at 27 million metric tons (2). VC is used in industry to produce polyvinyl
chloride (PVC), a plastic involved in commercial production. Facilities that
manufacture PVC products emit VC gas into the air as a waste product. VC is also
present as a solvent at many EPA Superfund sites across the United States. Aside
from being a direct contaminant at these sites, VC is a degradation product of other
chlorinated chemicals such as trichloroethylene (TCE; ATSDR rank #16)
tetrachloroethylene (PCE; ATSDR rank #33) and dichloroethene (DCE; ATSDR
rank #216) via soil microorganisms (3). Owing to its widespread prevalence, VC is
present in landfill leachates and many military Superfund sites across the country.
For example, up to 1,000,000 military, civilian personnel, and their families were
exposed to VC at Camp Lejeune, NC alone (3). Additionally, more than 80,000
American chemical workers have been occupationally exposed to VC (4, 5).
VC is present in the air surrounding production facilities at significant
concentrations. A major route of environmental exposure stems from
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contaminated groundwater. Residential areas surrounding both manufacturing and
Superfund sites are susceptible to VC migrating through soil and home foundations
where it readily volatilizes to enter showers, basements, and living spaces where
these vapors can recirculate (4, 5). Due to the high risk of low-level human
exposure in residential areas around VC-using facilities, understanding the effects
of this toxicant on human health is necessary, but current knowledge is sparse on
low-level VC exposure.
The major target of VC exposure is the liver. VC is a known hepatotoxicant
and at high, occupational levels of exposure, VC can cause steatosis (fat
accumulation), inflammation (steatohepatitis), fibrosis, and necrosis (6). Recently,
a pathology unique to VC exposure has been described, toxicant-associated
steatohepatitis (TASH), in chemical plant workers occupationally exposed to VC
(7, 8). These individuals showed most of the typical clinical signs of liver injury.
Within that cohort, 84% of patients exhibited hepatic steatosis and 85% exhibited
steatohepatitis. However, of the patients with steatohepatitis, only 55% went on to
develop fibrosis. Interestingly, plasma transaminase levels, which are typically
elevated with liver injury, were at normal levels in these individuals (8). Although
the effects of high level VC exposure have been studied, the effects of low level
exposure and its interactions with other risk-modifying factors, such as diet or
alcohol consumption, on hepatic and overall health have not been determined.
Therefore, it is crucial that these knowledge gaps are filled.
II.

Liver Diseases
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The liver is a major site of nutrient metabolism, detoxification, and is crucial
to maintaining a healthy digestive system. Liver function is determined not only by
genetics, but by diet, alcohol consumption, and toxicant exposure. As such, the
liver is susceptible to injury from a variety of agents. The most common
manifestation of liver damage is fatty liver disease (FLD), which is characterized
by an accumulation of triglycerides in the liver (9). Depending on the source of the
insult, it can be termed alcoholic liver disease (ALD) or non-alcoholic fatty liver
disease (NAFLD). Both diseases share similar pathological manifestations, but
have unique etiologies. In general, liver disease is a spectrum of pathologies
ranging from benign steatosis to active inflammation (steatohepatitis) to fibrosis,
cirrhosis (10), and potentially, hepatocellular carcinoma (11, 12). Processes
hypothesized that contribute to the initiation and progression of FLD include
lipotoxicity, (13) oxidative stress (13, 14) and inflammation (15, 16).
Although many people have FLD, only a fraction of that population will
progress from steatosis to a more severe form of the disease, such as
steatohepatitis (17, 18). Many factors play a role in determining severity of disease
and its progression, including genetics and environmental agents. Due to an
increase in triglycerides within hepatocytes, regular fatty acid metabolism is
disrupted, leading to alterations in other metabolic pathways such as protein and
carbohydrate metabolism (19).These changes on a molecular level cause the liver
to be more susceptible to insult from a second agent, such as VC. The effects of
low-level VC exposure on underlying liver injury have not been studied.

3

It is known that the liver becomes susceptible to injury from a second agent
after changes occur in response to a first agent (20, 21). For example, Yang et al.
(21) demonstrated that livers from genetically obese (fa/fa) rats have enhanced
sensitivity to inflammation produced by the injection of bacterial lipopolysaccharide
(LPS) compared to their lean littermates; this exacerbation of liver damage is
characterized by a more robust inflammatory response and enhanced cell death.
Recent studies from our group have demonstrated that sub-hepatotoxic doses of
a major VC metabolite, chloroethanol (CE), enhanced liver injury in response to
LPS administration in a murine model (22). In that study, animals who received CE
alone showed no histological changes in their liver tissue morphology. However,
on a protein level, many key metabolic enzymes were altered. There was also an
increase in steatosis and a decrease in glycogen stores, indicating alterations in
lipid and carbohydrate metabolism. The combination of both CE and LPS caused
enhanced damage when compared to either exposure alone as characterized by
enhanced inflammatory cytokine expression, histology and gross liver damage
(22). This study demonstrates a proof-of-concept that low levels of a VC metabolite
can enhance liver injury caused by LPS administration. Alterations in hepatocyte
metabolic enzymes and pathways that are not overly toxic can sensitize the liver
to be more susceptible to an insult from another agent. Although the hypothesis of
multiple “hits” in liver injury progression is not a new one, the application of this
paradigm to explore low-level VC exposure and underlying liver damage is novel.
A. Alcohol and the liver
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Millions of people worldwide consume alcoholic beverages. According to
the World Health Organization (WHO), 3.3 million (5.9%) of deaths worldwide are
due to the harmful use of alcohol (23). ALD encompasses several pathologies from
mild fat accumulation (steatosis), liver inflammation (alcoholic steatohepatitis;
ASH), to severe fibrosis, and cirrhosis (end-stage liver disease). Cirrhosis of the
liver is the 12th leading cause of death in the United States and in 2013, nearly
50% of all liver disease-related deaths were caused by ALD (24).
As the liver is the primary location of alcohol metabolism, it is the organ
most affected by alcohol-induced injury. Alcohol is metabolized via alcohol
dehydrogenase (ADH1), mitochondrial aldehyde dehydrogenase (ALDH2), and
CYP2E1. A majority of its detrimental effects are a result of its toxic metabolite,
acetaldehyde, accumulation, induction of an inflammatory response, and oxidative
stress (25).
In ALD, steatosis can be caused directly by ethanol metabolites’ disruption
of the balance between NAD+ and NADH, leading to inhibition of β-oxidation and
an accumulation of free fatty acids (FFA) and triglycerides (25). Alcohol exposure
can also alter transcription factors that mediate lipid-metabolizing enzymes. For
example, acetaldehyde can directly upregulate sterol regulatory element-binding
protein 1c (SREBP-1c) resulting in an increase in lipogenesis. Conversely,
acetaldehyde interacts with the DNA binding domain of peroxisome proliferator
activator protein alpha (PPARα), which inhibits the breakdown of FFA via βoxidation (18). Combined, the result is an increase of lipids within the tissue.
Another major mediating factor of alcohol-induced liver injury is the inflammatory
5

response, particularly the cytokine tumor necrosis factor alpha (TNFα). Upon
stimulation by alcohol consumption, TNFα is released from the liver’s resident
macrophages, known as Kupffer cells. It is upregulated and is involved in tissue
damage in response to alcohol exposure (26). The production of TNFα results in
recruitment of other inflammatory cells, such as neutrophils, as their infiltration into
tissue results in a more pronounced inflammatory response (18).
The combination of increased hepatic lipids and increased cytokine and
inflammatory cell recruitment allows for a cyclic pattern of liver damage. If alcohol
consumption continues, injury worsens and is a risk factor for developing more
serious injury. Due to the fact that VC and alcohol share several mechanisms of
liver injury, alcohol consumption may be a risk factor for developing more serious
liver disease when co-exposed with VC.
B. Obesity and the liver
Over 30% of US adults are obese (BMI ≥ 30) with another >30% being
overweight (BMI = 25-30) (27).This metabolic syndrome is characterized by insulin
resistance, hypertension, and dyslipidemia (28). Due to overconsumption of
dietary fats, NAFLD is a major hepatic manifestation of obesity and it was recently
estimated that 25% of the global population has NAFLD (29). Hepatic steatosis
occurs when the balance between fatty acid synthesis and uptake is greater than
its oxidation (30). This causes a disruption in energy homeostasis and an
accumulation of lipid droplets to occur within the liver tissue. NAFLD is also
associated with other metabolic dysfunction manifestations such as insulin
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resistance and type 2 diabetes, and can be mediated by the inflammatory
response (31).
Within the past decade, the perceived role of adipocytes has shifted from
simple lipid storing vessels to more complex mediators of metabolic, hormonal,
and inflammatory responses (32). Obesity causes an increase in the size of
adipocytes within adipose tissue and immune cells, such as macrophages, are
able to infiltrate into the adipose tissue and release cytokines such as TNFα and
interleukin-6 (IL-6) (33, 34), which cause further stress and are able to travel
through circulation and exert effects on the liver and other organs. In addition to
the cytokines being released from the adipose tissue, an increase in hepatic
adiposity also results in an increase in hepatic pro-inflammatory cytokine release.
These cytokines, like TNFα, activate Kupffer cells, which then release more
inflammatory signals and cause tissue damage (35). These metabolic changes
within hepatocytes, such as lipid accumulation, make these cells more susceptible
to insults from other factors and may result in exacerbated liver injury upon coexposure with toxicants, such as VC.
III.

VC Mechanism
A. VC metabolism
As mentioned previously, VC is metabolized by many of the same enzymes

that are involved in alcohol metabolism. After exposure via inhalation, absorption
is rapid and distribution is widespread. Due to the fact that the enzymes involved
in VC metabolism are primarily located in the liver, it is the most sensitive to VC
exposure. There are several pathways that VC can be metabolized into its reactive
7

intermediates which all follow Michaelis-Menten enzyme kinetics (36). The first
pathway involves microsomal mixed function oxidases, primarily CYP2E1, which
oxidizes VC to 2-chloroethylene oxide, which is then conjugated to glutathione and
excreted. An alternate pathway of VC metabolism is oxidation to 2-chloroethanol.
2-chloroethanol can then enter into the same pathway as ethanol metabolism. It is
transformed into 2-chloroacetaldehye by alcohol dehydrogenase. Aldehyde
dehydrogenase converts 2-chloroacetaldehyde into chloroacetic acid which is then
conjugated to glutathione and excreted in urine, ultimately, as thioacetic acid (37).
VC is inhaled and absorbed through the lungs and its half-life is relatively
short, being only a few hours. Therefore, it is not likely that VC gas directly
damages tissue. Its two main reactive metabolites, chloroethanol (CE) and
chloroactealdehye (CAA), are able to enter cells and cause damage. Once inside
the cell, VC metabolites are able to generate reactive oxygen and nitrogen species
(ROS/RNS) and form protein adducts. These then go on to further damage the
cells by causing oxidative damage, increasing inflammatory cytokine recruitment
(22), and increasing endoplasmic reticulum (ER) stress.
B. VC metabolites damage mitochondria
Mitochondria are essential to the health of all cells as they produce ATP
and regulate major cell death pathways such as apoptosis and necrosis.
Mitochondria respond dynamically to stress, nutritional status, and environmental
signals. It has been hypothesized that the VC metabolite, CAA, inhibits oxidative
phosphorylation in mitochondria (38, 39) and our group has recently shown that
CAA is mitotoxic in vitro and ex vivo. Data from that study demonstrate that CAA
8

decreases mitochondrial membrane potential in a concentration-dependent
manner, and with increasing concentrations, decreases plasma membrane
potential as well. This finding was corroborated by cellular bioenergetics analyses
that showed a decrease in ATP production and decreased oxygen consumption
rate with increasing CAA concentrations (22).
Another aspect of mitochondrial damage besides impaired function is the
accumulation and elimination of damaged mitochondria. This is accomplished by
the complex process of autophagy.
C. Autophagy
Autophagy is the intracellular process of “self-eating” or degradation of
macromolecules and organelles during times of starvation or stress to provide
nutrients or to protect the cell. Autophagy is a highly conserved process and as
such so are the proteins involved. Several autophagy related genes (Atg’s) have
been identified along with associated proteins which aid in the degradative process
(40, 41). There are four main phases of autophagy (Figure 1). The first involves
initiation and formation of the autophagosome. It begins as an isolated membrane
portion (the phagophore) from the ER or golgi apparatus (42). Through nucleation
and expansion of the membrane, the phagophore becomes an autophagosome; a
double membraned structure that engulfs targeted macromolecules, proteins, or
organelles for degradation. The autophagosome matures and fuses with a
lysosome, releasing its contents for enzymatic degradation (43).
Autophagy is crucial for normal cell homeostasis and has been shown to be
a critical player in several models of liver disease. Its activation has been shown
9

Figure 1. Scheme of autophagic pathway. The main stages of autophagy are
depicted. Autophagy begins with introduction or initiation of the process. This is
followed by nucleation, phagophore formation, and autophagosome expansion.
Finally, the autophagosome fuses with a lysosome and degradation of its contents
(44).
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to be protective (45-47) while its inhibition has been associated with increased liver
damage (48, 49). One probable mechanism of its protective effects is the removal
of damaged organelles, such as mitochondria (mitophagy) (50, 51). If the affected
cells are unable to clear and degrade damaged mitochondria, their accumulation
would add to the cellular injury and further impair normal cell function.
mTOR, (mechanistic target of rapamycin) is a major regulator of autophagy.
With mTOR being the major sensor for nutritional status of the cell, its activation
blocks initiation of autophagy while mTOR inhibition allows autophagy to proceed
(52). As mentioned previously, our group recently showed that mTOR is activated
in

mice

administered

VC

metabolites

alone.

We

hypothesize

that

pharmacologically inhibiting mTOR with rapamycin would allow us to determine if
autophagy inhibition is involved in liver damage caused by VC metabolite
exposure.
IV.

Overall significance
VC is present in the ambient air and ground water surrounding chemical

and PVC production facilities, making residents living in those areas at risk for lowlevel VC exposure. Many of the at-risk areas are urbanized and of a lower
socioeconomic status than more suburban residential areas. Other risk factors
associated with highly urban populations are an increased risk for alcohol
consumption and a high fat diet resulting in being overweight or obese. Both of
these factors cause changes on the molecular level in the liver, such as steatosis,
and cause these individuals to be more susceptible to a second hepatic insult.
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There is a knowledge gap regarding co-exposure of underlying liver disease
such as ALD or NAFLD and the effects of low-level, subclinical VC exposure.
Therefore, the goals of the current work are two-fold: a) to determine whether VC
exposure may be acting to enhance liver injury in underlying ALD and b) to
determine the role of mTOR in liver injury progression caused by VC exposure and
whether or not activation of autophagy could have protective effects in an
experimental model of liver injury involving VC metabolites and LPS.
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MATERIAL AND METHODS
I.

Animals and Treatments

Eight week old, male C57BL/6J mice from Jackson Laboratory (Bar Harbor, ME)
were housed in a pathogen-free barrier facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care, and procedures were
approved by the local Institutional Animal Care and Use Committee.
A. Acute-on-chronic alcohol exposure
Mice were fed either an ethanol-containing Lieber-DeCarli diet or an iso-calorically
matched control diet. Because of the relatively high caloric content of ethanol, pairfed control animals received an iso-caloric control diet; the calories in the isocaloric diet were matched by adding a calorie equivalent of maltose-dextrin. During
the exposure period, animals were housed in pairs in shoebox cages in a room
held at 75˚F. Diet was provided in vacuum tubes and replaced between 3 and 5
pm daily. Both ethanol-fed animals and their pair-fed counterparts received control
diet for the first five days of liquid diet feeding to allow acclimation to the liquid diet
feeders. On the sixth day, ethanol-fed animals received diet containing 5% (vol/vol)
ethanol. They continued to receive the ethanol-containing diet for 10 days. On the
eleventh day, the two diet groups were further separated into additional groups
that either received a bolus gavage of chloroethanol (CE; 50 mg/kg) or vehicle
(saline), modified from Bertola et al., (53). The concentration of CE was
13

determined by others to not directly cause liver damage (54) and was validated
(22); mice were ethanol fasted for 4 hours prior to oral gavage and were sacrificed
4, 9, or 24 hours later (Figure 2A).
B. Rapamycin administration
Mice were administered CE (50 mg/kg) via oral gavage. One hour after, rapamycin
(1mg/kg, i.p., LC Laboratories, Woburn, MA,) was administered. 24 hours after CE
administration, mice were administered LPS (E. Coli, 10 mg/kg, i.p., Sigma, St.
Louis, MO) and sacrificed 24 hours later (Figure 2B).
C. Sample collection
At the time of sacrifice, animals were anesthetized with ketamine/xylazine (100/15
mg/kg, i.p.). Blood was collected from the vena cava just prior to sacrifice
(exsanguination), and citrated plasma was stored at -80°C for further analysis.
Portions of liver tissue were snap-frozen in liquid nitrogen, embedded in frozen
specimen medium (Sakura Finetek, Torrance, CA), or were fixed in 10% neutral
buffered formalin.
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A.

Chloro

B.
CE

Rapa

LPS

-24 h

-23 h

0h

Sacrifice
+24 h

Figure 2. Timelines of experiments. Panel A shows the NIAAA model timeline
modified with the CE bolus gavage on the eleventh day. Panel B depicts the
timeline for CE, rapamycin, and LPS administration.
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II.

Biochemical Analysis

Plasma activity levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were determined spectrophotometrically using standard
kits (Thermotrace, Melbourne, Australia).
III.

Histology
A. General Morphology

Formalin fixed, paraffin embedded liver tissue was cut at 5 μm and mounted on
charged glass slides. Sections were deparaffinized with Citrisolv (Fisher Scientific,
Waltham, MA) and rehydrated through addition of graded ethanol solutions.
Sections were then stained with hematoxylin and eosin (H&E). After staining,
samples were dehydrated through graded alcohol, washed in Citrisolv and then
mounted with Permount (Fisher, Waltham, MA).
B. Neutrophil accumulation
Neutrophil accumulation in liver tissue was measured using chloracetate esterase
(CAE) staining. Briefly, formalin fixed, paraffin embedded liver tissue was cut at 5
μm and mounted on charged glass slides. Sections were deparaffinized with
Citrisolv (Fisher, Waltham, MA) and rehydrated through addition of graded
solutions of ethanol. Tissue specimens were incubated in a solution of napthol ASD chloroacetate (1 mg/ml) in N,N-dimethylformamide, with 4% sodium nitrite and
4% new fuchsin. The napthol AS-D chloroacetate is enzymatically hydrolyzed by
chloroacetate esterase in neutrophils, liberating the napthol compound. Napthol
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combines with a freshly formed diazonium salt, leaving bright pink color deposits
at the site of enzymatic activity.
C. Apoptosis
Apoptosis was detected via terminal deoxynucleotidyl transferase biotin-dUTP nick
end labeling (TUNEL; Millipore, Billerica, MA). In brief, formalin fixed, paraffin
embedded liver tissue was cut at 5 μm and mounted on charged glass slides.
Sections were deparaffinized with Citrisolv (Fisher, Waltham, MA) and rehydrated
through graded ethanol. Tissue samples were processed according to the TUNEL
kit protocol. TUNEL-positive cells (hepatocytes and non-parenchymal cells, NPCs)
were counted using Image J software and are expressed as positive cells per 1000
hepatocytes.
D. Metabolism
Lipid accumulation was detected via Oil Red-O (ORO) staining. Frozen sections
of liver were cut at 10 μm and stained with Oil Red-O solution (Sigma, St. Louis,
MO) for 10 minutes, washed, and counterstained with hematoxylin for 45 seconds.
Samples were then mounted with Permount (Fisher, Waltham, MA). Hepatic
glycogen reserves were visualized as a dark purple color using Periodic Acid-Schiff
(PAS) staining. Formalin fixed, paraffin embedded liver tissue was cut at 5 μm and
mounted on charged glass slides. Sections were deparaffinized with Citrisolv
(Fisher, Waltham, MA) and rehydrated through graded ethanol. Sections were
incubated in 0.5% Periodic Acid solution for 5 minutes, washed in water, and
incubated with Schiff reagent for 15 minutes. Samples were then counterstained
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with hematoxylin for 45 seconds, washed in water, dehydrated through graded
ethanol, washed in Citrisolv, and then mounted with Permount.
IV.

Immunoblots

Liver samples were homogenized in RIPA buffer (55), containing protease and
phosphatase inhibitor cocktails (Sigma, St. Louis, MO). Samples were loaded onto
SDS-polyacrylamide gels (Invitrogen, Thermo Fisher Scientific, Grand Island, NY),
followed by electrophoresis and Western blotting onto PVDF membranes (Hybond
P, GE Healthcare Bio-Sciences, Pittsburgh, PA). Primary antibodies against
phosphorylated and total mTOR, total GAPDH, and total LC-3 I/II (Cell Signaling
Technology; Beverly, MA) were used. Densitometric analysis was performed using
UN-SCAN-IT gel (Silk Scientific Inc., Orem, UT) software.
V.

RNA Isolation and Real-Time RT-PCR

RNA was extracted immediately following sacrifice from fresh liver samples using
RNA Stat60 (Tel-Test, Ambion, Austin, TX) and chloroform. RNA concentrations
were determined spectrophotometrically and 1 µg of total RNA was reverse
transcribed using a kit (Quanta Biosciences, Gaithersburg MD). Real-time RTPCR was performed using a StepOne real time PCR system (Thermo Fisher
Scientific, Grand Island, NY). Primers and probes were ordered as commercially
available kits (Thermo Fisher Scientific, Grand Island, NY). The comparative CT
method was used to determine fold differences between the target genes and an
endogenous reference (18S).
VI.

Statistical Analyses
18

Results are reported as means ± SEM (n = 4-8) and were analyzed using
SigmaPlot 11.0 (Systat Software, Inc., San Jose, CA). ANOVA with Bonferroni’s
post-hoc test (for parametric data) or Mann-Whitney Rank Sum test (for
nonparametric data) were used for the determination of statistical significance
among treatment groups, as appropriate. A p value less than 0.05 was selected
before the study as the level of significance.
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RESULTS
CE exacerbates liver injury caused by ethanol
In order to assess status of overall liver health in the given groups, plasma
transaminase levels were measured as an index of liver injury. Figure 3A shows
plasma transaminase levels at 4, 9, and 24 hours after CE administration. Pair-fed
mice that did or did not receive CE showed no elevation in either ALT or AST at
any time point. However, ethanol-fed mice who received CE show a significant
increase in AST levels at the 24 hour time point. Figure 3B depicts representative
photomicrographs of general liver morphology at the 9 hour time point as seen
through H&E staining. Neither pair-fed control nor pair-fed CE animals showed
signs of tissue damage. Ethanol-fed animals showed an increase in inflammatory
cell infiltration. CE enhanced these effects, increasing inflammatory and necrotic
foci as highlighted in Figure 3B with an arrow.
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Figure 3. CE enhances ethanol-induced liver injury. Plasma transaminases (A)
and representative photomicrographs for paraffin-embedded liver sections stained
for H&E at 9 hours (B) are shown (200x). Ethanol-fed, CE administered animals
show elevated AST levels at the 24 hour time point and damaged liver morphology
at the 9 hour time point. a, p<0.05 compared to pair-fed controls.
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CE enhances ethanol-induced steatosis
Ethanol feeding is known to enhance steatosis in models of liver injury (53). In line
with this, Figure 4 depicts lipid accumulation in the liver visualized via ORO
staining. Pair-fed control animals showed no increase in ORO staining and CE
alone did not significantly increase ORO positive staining. However, ethanol
increased ORO positive staining. CE enhanced the intensity of ORO staining in
ethanol-fed animals.
Rapamycin blunts liver damage caused by CE and LPS
In order to elucidate mechanisms by which CE acts as an enhancing factor in a
multiple-hit model, a more robust model of liver injury was used with CE + LPS, as
previously described by Anders et al., (22). To verify that rapamycin inhibited
mTOR activation, mTOR phosphorylation was analyzed via Western Blot (Figure
5). No significant differences were observed between the groups. To examine the
effects of rapamycin on liver damage, plasma transaminase levels were analyzed
(Figure 6A). Control, CE alone, and CE with rapamycin administered animals show
normal transaminase activity. LPS alone increased ALT and AST values and CE
enhanced this effect. Significantly, the addition of rapamycin attenuated both ALT
and AST values. Liver morphology was examined via H&E staining and CAE
positive cells were visualized as an index of neutrophil infiltration (Figure 6B).
Control animals show normal morphology and little CAE positive staining. LPS
caused inflammatory foci and an increase in CAE positive cells, CE enhanced this
effect. Notably, rapamycin administration resulted in more normal morphology and
fewer CAE positive cells.
22

Pair-fed, control

Pair-fed, CE

EtOH, control

EtOH, CE

Figure 4. CE’s effect on ethanol-induced steatosis. Representative
photomicrographs are depicted for frozen liver sections stained with ORO for lipids
as described in Materials and Methods (200x).
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Figure 5. Rapamycin’s effect on mTOR activity. Western Blot for
phosphorylated mTOR and GAPDH (A) are depicted and densitometry analysis
was used to analyze differences amongst groups (B) as described in Materials and
Methods.
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Figure 6. Rapamycin blunts liver injury caused by CE + LPS. Plasma
transaminase levels (A) and representative photomicrographs for paraffinembedded livers stained with H&E and CAE (B) are shown as described in
Materials and Methods. (200x). Data are reported at mean ± SEM. a, p<0.05
compared to control, b, p<0.05 compared to LPS alone, c, p<0.05 compared to CE
+ LPS.
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Effect of rapamycin on changes in apoptosis caused by CE and LPS
The type of cell death has been shown to play an important role in many models
of liver injury. Indeed, previously it has been shown that VC causes necrotic rather
than apoptotic cell death (8, 22). In order to determine the cell death pathway in
this model of injury, TUNEL-positive cells were visualized as an index of apoptosis
and TUNEL-positive hepatocytes and non-parenchymal cells were counted.
Consistent with previous work with this model, an increase of TUNEL-positive cells
with LPS administration and a decrease in that number with the addition of CE was
observed (22). Importantly, the administration of rapamycin significantly attenuates
the number of TUNEL-positive hepatocytes as seen in Figure 7B, while it had no
effect on the number of TUNEL-positive non-parenchymal cells.
Rapamycin’s effect on changes in carbohydrate and lipid metabolism caused by
CE and LPS
It is known that CE alone causes alterations in hepatic metabolic pathways (22).
In order to explore the effects of mTOR inhibition on lipid and glycogen levels in
liver tissue, ORO staining for lipids (Figure 8A) and PAS for glycogen (Figure 8B)
were visualized. LPS alone caused an increase in ORO positive staining and a
depletion of glycogen reserves. The combination of both CE and LPS resulted in
enhanced ORO positive staining and almost complete depletion of hepatic
glycogen stores. Notably, the addition of rapamycin prevented glycogen depletion
and attenuated the accumulation of lipids.
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Figure 7. Rapamycin blunts number of TUNEL-positive cells. Representative
photomicrographs of paraffin-embedded liver stained for TUNEL-positive cells are
depicted (A) and positive cells were counted (B) as described in Materials and
Methods (200x). Data are reported at mean ± SEM. a, p<0.05 compared to control,
b, p<0.05 compared to LPS alone, c, p<0.05 compared to CE + LPS.
.
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Figure 8. Rapamycin’s effect on lipid and glycogen stores. Representative
photomicrographs of frozen liver sections stained with ORO (top) and paraffinembedded liver sections stained with PAS for glycogen (bottom) are depicted as
described in Materials and Methods (200x).

28

Rapamycin blunts CE and LPS induced inflammatory cytokine expression
In order to determine the effect of mTOR inhibition on the inflammatory response,
hepatic mRNA expression was analyzed to determine relative levels of pro- and
anti-inflammatory markers. As mentioned in the introduction, TNFα is a major
cytokine involved in liver inflammation. Plasminogen activator inhibitor-1 (PAI-1),
a mediator of inflammation, is involved in liver injury progression (56). IL-6 and IL1β are pro-inflammatory cytokines involved in the acute-phase inflammatory
response (57). Interleukin-10 (IL-10) is an anti-inflammatory cytokine and can be
protective during liver inflammation (58). Inducible nitric oxide synthase (iNOS) is
activated by pro-inflammatory cytokines and contributes to the inflammatory
process (59). Across all markers, there was an increase in expression with LPS
alone. As expected, the combination of CE and LPS enhanced expression of Tnfα,
Pai-1, Il-6, iNos Il-1β, and Il-10. Rapamycin administration resulted in a significant
blunting of Pai-1, iNos, Il-1β and Il-10 expression, indicating an attenuation of the
inflammatory response. However, no significant differences were observed for
Tnfα or Il-6 expression with rapamycin.
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Figure 9. Rapamycin’s effect on inflammatory cytokines. Hepatic mRNA
expression data for inflammatory mediators were measured by qRT-PCR are
shown. Data are reported at mean ± SEM. a, p<0.05 compared to control, b, p<0.05
compared to LPS alone, c, p<0.05 compared to CE + LPS.
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Autophagy marker changes with CE, LPS and rapamycin
Rapamycin’s allosteric inhibition of mTOR is known to result in an induction of
autophagic processes (45-47). Several markers are indicative of autophagy
progression and activation. Atg 5 is necessary for the formation and elongation of
the autophagosome (60). Rapamycin and CE administered animals showed a
significant increase in Atg 5 expression. LPS caused no increase in Atg5
expression, however there was a significant increase in expression with CE and
LPS with and without rapamycin. No differences were observed between those
groups. Microtubule associated protein-1 light chain 3 (LC-3) is cleaved and
conjugated to phosphatidylethanolamine to form LC-3 II which remains associated
with the autophagosomal membrane until ultimate fusion with the lysosome (41,
61, 62), and has been used as a marker of autophagy progression. LC-3 II protein
was observed via Western Blot. There were no significant differences across the
groups.
A major target of autophagic degradation is cellular inflammatory machinery known
as the inflammasome. Therefore, mRNA expression of a protein involved in
inflammasome formation, NLR family pyrin domain containing 3 (NLRP3), was
analyzed. A significant increase was observed with LPS administration. There was
also a significant increase with CE and LPS with or without rapamycin, but no
differences were observed amongst the groups.
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Figure 10. Rapamycin’s effect on autophagy markers. LC-3 protein was
analyzed by Western Blot (A) and densitometry was used to analyze differences
across groups (B) as described in Material and Methods. mRNA expression of
markers of autophagy (Atg5) and inflammasome activity (Nlrp3) were measured
by RT-qPCR (C). Data are reported as the mean ± SEM. a, p<0.05 compared to
control, b, p<0.05 compared to LPS alone.
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DISCUSSION
Since the realization that high, occupational exposure to VC was
hepatotoxic, workplace regulations have been implemented to avoid this severe
type of exposure (63). However, PVC producing facilities still release VC as a
waste product into the environment. This potentially puts the individuals around
these facilities at risk for low-level, chronic VC exposure. As humans are rarely
exposed to one factor at a time, other exposures, such as alcohol consumption or
diet, may modify risk for developing more severe liver injury upon co-exposure with
low-level VC.
CE enhances ethanol-induced liver injury and steatosis
Alcohol consumption is a common risk-modifying factor for the development
of more severe liver diseases, especially upon exposure with other modifying
factors, such as VC. Since alcohol abuse is common in urban areas (64), the first
goal of this project was to examine the potential risk for alcohol and low-level VC
co-exposure using a novel model for liver injury modified from the NIAAA acuteon-chronic model (53). In the NIAAA model, mice are given alcohol-containing diet
for 10 days followed by a binge dose of ethanol on the final day in order to examine
a more relevant pattern of human alcohol exposure. Here, this model was adapted
for the purpose of examining a potential synergistic effect of two known liverdamaging agents, alcohol and VC. With the modified model, mice were
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administered CE instead of an ethanol binge on the final day. Indeed, increased
liver injury was observed when animals were exposed to both ethanol and CE
(Figure 3). Chronic ethanol exposure induces its metabolizing enzyme, CYP2E1.
(65). Acetaminophen toxicity is known to be enhanced in individuals who consume
alcohol because the two compounds share metabolizing enzymes. Ethanol is
preferentially metabolized by ADH, causing acetaminophen to be alternately
metabolized to its toxic metabolite via CYP2E1, which accumulates and causes
severe liver injury (66). However, in this model, CE is the toxic metabolite of VC
and as such, the already induced CYP2E1 more efficiently metabolizes CE.
Therefore, less accumulation of CE is not as damaging, resulting in less tissue
injury and inflammation.
Serum AST levels were significantly elevated at the 24 hour time point in
animals who received the ethanol diet and CE, although no differences were seen
in ALT levels at any time point. AST is known to be present in both hepatocyte
cytoplasm and mitochondria and its isolated elevation is attributed to release from
non-hepatic tissue, particularly damaged muscle (67). However, previous data (22)
gives evidence that VC metabolites damage hepatic mitochondria. Therefore, the
addition of CE to already injured hepatocytes is sufficient to cause damage to
those mitochondria and release AST. The ratio of AST to ALT values can be a
useful tool when determining cause of liver damage. When AST and ALT values
respond the same, it is indicative of an acute viral or toxicant induced liver injury
due to the release of only the cytoplasmic enzymes. However, when AST values
are higher than ALT values, it is indicative of alcohol-induced liver injury and due
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to the release of the mitochondrial AST from necrotic cell death (68, 69). Therefore,
the isolated elevated AST levels could be attributed to the ethanol-feeding alone.
However, the addition of CE significantly enhanced AST levels compared to
ethanol-fed control animals, suggesting a synergistic effect on liver damage.
In ALD, steatosis is seen in 90% of subjects who consume significant
amounts of alcohol (70). Here, steatosis was observed in ethanol-fed animals
(Figure 4). Ethanol-fed animals mainly showed evidence of macrovesicular lipid
droplets, being indicative of triglyceride accumulation. However, the presence of
both micro- and macrovesicular lipid droplets was seen with the addition of CE,
indicating an accumulation of FFA and triglycerides, respectively. The presence of
microvesicular lipid droplets and their associated FFA have detrimental effects on
cellular function and sensitizes the liver to be more susceptible to more severe
injury (71). FFA accumulation has also been shown to be indicative of impaired
mitochondrial β-oxidation (72), which is in line with previous data that VC
metabolites are damaging hepatic mitochondria. Indeed, the addition of CE in
ethanol-fed animals resulted in enhanced steatosis as seen by the presence of
microvesicular lipid droplets, indicative of FFA accumulation and impaired
mitochondrial function in this model.
mTOR activation is critical in CE-induced liver injury
Exploring the interaction and possible multiple-hit phenomenon with ethanol
and VC co-exposure resulted in interesting findings. However, we were interested
in examining the mechanisms by which VC acts as a risk-modifying factor for
underlying liver disease. Therefore, another model of liver injury established at the
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same time in our laboratory was also employed to characterize molecular changes
and mechanistic endpoints in response to VC metabolite exposure. In that model,
our laboratory demonstrated that administration of the VC metabolite, CE, alone
was sufficient to alter metabolic enzyme expression although no hepatic tissue
damage was observed (22). With the addition of LPS administration, liver damage
was enhanced in animals exposed to CE. Findings from that study include
enhanced liver damage, neutrophil infiltration, oxidative stress, and metabolic
dysfunction. Alterations of key metabolic enzymes were observed some which
include mTOR, AMP-activated protein kinase (AMPK), and protein kinase B or
AKT. Specifically, a significant activation of mTOR was observed in mice who were
administered CE alone. Therefore, the second goal of this project was to
investigate the role of mTOR in liver injury caused by VC metabolite exposure.
mTOR inhibition blunts CE-induced metabolic changes
mTOR activity is known to be dysregulated in several disease states (73)
and its inhibition has been shown to be protective in many models of liver injury
(74, 75). A common method of mTOR inhibition involves administration of
rapamycin. Rapamycin has anti-proliferative and immunosuppressive effects (76).
It also enhances autophagy processes by allosteric inhibition of mTOR complex I
(77). The metabolic profiles of animals in this experiment were analyzed
histologically through ORO and PAS stains for lipids and glycogen, respectively.
The addition of rapamycin blunted the accumulation of hepatic lipids and prevented
glycogen depletion, indicative of a protective effect on hepatocyte metabolism.
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One possible mechanism by which rapamycin attenuated lipid accumulation
is by affording mitochondrial protection from CE. Mitochondrial protection results
in unhindered oxidative phosphorylation and β-oxidation. With oxidative respiration
intact, the switch to anaerobic respiration (glycolysis) and subsequent glycogen
depletion was not required. Additionally, Singh et al. demonstrated that autophagy
is crucial for regulating lipid metabolism via an autophagic process unique to lipid
droplets, lipophagy (78). Lipophagy is a specific type of autophagy in which lipid
droplets are sequestered and enzymatically degraded by lysosomes (79). Lin and
colleagues showed that induction of autophagy was protective against both alcohol
and NAFLD-induced hepatic steatosis and reduced liver injury (80). Therefore, the
results of this model of liver injury suggest that autophagic activity can blunt hepatic
lipid droplet formation via lipophagy. FFA are known to be lipotoxic and preventing
their accumulation would afford another mechanism of protection by rapamycin
administration.
mTOR inhibition attenuates CE-induced liver injury
Upon rapamycin administration, the liver damage and inflammation
observed with LPS and CE was significantly attenuated (Figures 6 and 9). Chen
et al., demonstrated in a murine model of methionine-choline deficient diet induced
NASH, that rapamycin decreased histological damage, decreased Il-1β
expression, and decreased myeloperoxidase activity, indicative of less neutrophil
infiltration (84). Here, rapamycin administration significantly attenuated hepatic
mRNA expression of inflammatory markers such as iNos, Il-10, and Il-1β. A
significant attenuation of both ALT and AST liver enzymes was also observed.
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Histologically, a normal gross morphology and fewer CAE positive cells were
observed in rapamycin-administered animals, indicating that, indeed, mTOR is
crucial for VC metabolite-induced injury. VC metabolite administration causes
mitochondrial damage and, consequently, a decrease in cellular energy levels
leading to cell death and injury (22). ROS and RNS, produced by damaged
mitochondria, mediate hepatocyte inflammation and account for the increased
injury observed. The data support that rapamycin attenuates injury via
mitochondrial protection by increasing mitophagy. Mitophagy alleviates the burden
of injured mitochondria within the cytoplasm by their degradation, which allows for
maintenance of mitochondrial homeostasis and provides protection against
enhanced damage (85). Indeed, rapamycin and CE administration caused a
significant increase in Atg5 mRNA expression (Figure 10C), supporting the
hypothesis of the autophagic process being active in this model.
In addition to its role in mediating cellular protection, autophagy is a known
negative regulator of inflammasome activity (86, 87). Inflammasomes are multiprotein complexes that assemble in the cytoplasm in response to pathogens or
cellular damage (88). A major function of inflammasome formation is caspase-1
activation and IL-1β maturation (87). The inflammasome complex NLRP3 is known
to be activated by ROS (89) and endogenous damage signals or damage
associated molecular patterns (DAMPs) such as high mobility group box 1 protein
(HMGB1) and heat shock proteins (90, 91). In this study, rapamycin significantly
blunted Il-1β expression, which suggests that enhanced autophagy and therefore
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elimination of excess, active inflammasomes may be important players in injury
attenuation.
Summary and conclusions
In conclusion, the current study demonstrated that VC metabolite exposure
may be one factor in a “multiple-hit” phenomenon of liver damage in two different
models. mTOR plays a critical role in VC metabolite-induced liver damage. Indeed,
its inhibition attenuated indices of liver damage and steatosis. Moreover, mTOR
inhibition caused blunting of key inflammatory mediator expression, attenuation of
lipid accumulation and prevention of glycogen depletion. Autophagy may be a
player in VC metabolite induced liver injury. Indeed, the data support that
autophagy afforded mitochondrial protection via mitophagy and provided a more
homeostatic lipid metabolic profile through lipophagy and degradation of excess,
lipotoxic FFA. Attenuated IL-1β expression with the addition of rapamycin suggests
that the inflammasome may be a key regulator in the progression of VC-metabolite
induced liver injury. However, further studies are necessary to analyze these
mechanisms in greater detail.
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Figure 11. Working hypothesis. Upon exposure to VC, 1) reactive solvent
intermediates form though bio activation processes and diet-induced obesity
decreases their elimination. 2) Through carbonyl stress and the generation of
reactive oxygen and nitrogen species (ROS/RNS), solvent metabolites cause ER
stress leading to the production of proinflammatory cytokines and mitochondrial
damage, which impairs oxidative phosphorylation; the cell increases flux through
anaerobic glycolysis to compensate for this loss of ATP yield. The increased
demand for glucose depletes glycogen stores 3) acetylCoA is being shunted to
lipid synthesis (causing steatosis) rather than β-oxidation, even under conditions
of ATP depletion. 4) The combined metabolic stress of solvent metabolite
exposure and ATP depletion likely causes ‘liponecrosis’ associated with increased
proinflammatory cytokines and inflammasome activation.
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STRENGTHS OF THIS WORK
There are many strengths of this work. This study demonstrated that subhepatotoxic levels of the VC metabolite, CE, enhanced liver damage in two
separate models of injury. We show that underlying liver injury caused by alcohol
is enhanced with co-exposure to CE. We also show that sub-hepatotoxic levels of
CE can enhance injury caused by the bacterial endotoxin, LPS. Another strength
of this work is identifying a novel role of mTOR in VC-induced liver damage. The
hypotheses that autophagy and the inflammasome are involved in VC-induced
liver injury are novel and this work lays a foundation for ongoing research with
those mechanisms.
The use of whole animal models in this work is also a strength. All of the
experiments here were performed in vivo. Liver injury and its mediating factors is
a complex process and as such is best observed at the level of the whole organism.
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PITFALLS AND FUTURE DIRECTIONS
Further work is needed in order to identify more detailed mechanisms
involved in mTOR’s inhibition in VC-metabolite induced liver injury. A major
limitation of this study is the 24 hour time point used. Future studies will be
conducted in order to analyze mRNA expression at 4 hours post LPS
administration, in addition to the 24 hour time point from this study. The time point
used yielded necessary insight for establishing this model and determining
pathology. However, an earlier time point will aid in gaining mechanistic insight to
injury progression. For example, it is foreseeable that we will see more pronounced
changes in mTOR and LC-3 protein levels via Western Blot analysis at an earlier
time point. Moreover, at the 4 hour time point, we expect to see more significant
differences with the rapamycin administered mice versus CE + LPS in both mRNA
and protein expression of inflammatory and autophagy markers.
Another limitation of this study was the use of the VC-metabolite, CE.
Although CE is a primary metabolite of VC, it is not the parent compound and
therefore may not completely recapitulate the effects seen with VC gas.
Future directions include expanding this model to exposing mice to VC gas
via an inhalation chamber and a high fat diet (HFD) to induce NAFLD. This will
better mimic human circumstances and exposures in the environment. We also
aim to examine the effects on mitochondria in response to VC and other factors in
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greater depth. Lastly, we are interested in employing rapamycin in the VC-HFD
model of liver injury to validate that mTOR is directly involved in injury progression
and that autophagy indeed plays a crucial role in damage.
CONCLUSIONS
A paradigm shift has occurred in the past years has been investigating the
impact of low, chronic exposures in contrast to high occupational acute exposures.
This approach attempts to take into account multiple factors and damaging agents
that may contribute to disease status. In this context, the impact of underlying
disorders that may modify risk is critical. Liver disease is not contributed to one
factor, rather is modified by other mitigating conditions, such as other
environmental or genetic factors. This study establishes that indeed, VCmetabolite exposure can have influence over severity of liver injury when coexposure occurs with other modifying factors.
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ABBREVIATIONS
VC

Vinyl chloride

ATSDR

Agency for toxic substances and disease registry

PVC

Polyvinyl chloride

TASH

Toxicant associated steatohepatitis

FLD

Fatty liver disease

ALD

Alcoholic liver disease

NAFLD

Non-alcoholic liver disease

LPS

Lipopolysaccharide

CE

Chloroethanol

FFA

Free fatty acids

TNFα

Tumor necrosis factor alpha

IL-6

Interleukin-6

IL-10

Interleukin-10

CAA

Chloroacetaldehyde

ROS/RNS

Reactive oxygen species, nitrogen species

Atg

Autophagy related

mTOR

Mechanism target of rapamycin

ALT

Alanine transaminase

AST

Aspartate transaminase

H&E

Hematoxylin and Eosin

CAE

Chloroacetate esterase

TUNEL

Terminal deoxynucleotidyl transferase biotin-dUTP nick end
labeling

ORO

Oil-Red O

PAS

Periodic Acid Schiff

NLRP3

NLR family pyrin domain containing 3

LC-3

Microtubule associated protein-1 light chain 3

HMGB-1

High mobility group box-1

DAMP

Damage associated molecular pattern
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